1-(2,6-dihydroxyphenyl)-1-propanone | 3361-72-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2,6-dihydroxyphenyl)-1-propanone
• 英文别名: 1-(2,6-dihydroxyphenyl)-propan-1-one；2,6-dihydroxypropiophenone；1-(2,6-Dihydroxy-phenyl)-propan-1-on；2-propionylresorcinol；1-(2,6-dihydroxyphenyl)propan-1-one
• CAS: 3361-72-6
• 化学式: C₉H₁₀O₃
• 分子量: 166.177
• InChiKey: PFOCGAIVMLXRNW-UHFFFAOYSA-N

物化性质

• 熔点：
  137–138°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2914501900

反应信息

• 作为反应物：
  描述：

  1-(2,6-dihydroxyphenyl)-1-propanone 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 10.0h， 生成 1-(2-hydroxy-6-(3-(p-tolylamino)propoxy)phenyl)propan-1-one
  参考文献：
  名称：

  Synthesis of propiophenone derivatives as new class of antidiabetic agents reducing body weight in db/db mice

  摘要：

  A series of propiophenone derivatives (6-23) have been synthesized and evaluated for their in vivo anti-hyperglycemic activities in sucrose loaded model (SLM), sucrose challenged streptozotocin (STZ-S) induced diabetic rat model and C57BL/KsJ db/db diabetic mice model. Compound 15 and 16 were emerged as potent antihyperglycemics and lipid lowering agents. These compounds (15, 16) further validate the potency by reducing body weight and food intake in db/db mice model. Possible mechanism of action for the propiophenone derivatives was established by the evaluation in various in vitro models. Interestingly some of the compounds were efficiently inhibiting PTP-1B. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.12.027
• 作为产物：
  描述：

  1,3-双(甲氧基甲氧基)苯 在 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 为溶剂， 反应 1.0h， 生成 1-(2,6-dihydroxyphenyl)-1-propanone
  参考文献：
  名称：

  设计和合成新型苯并呋喃，作为靶向真菌N-肉豆蔻酰基转移酶的新型抗真菌剂。第1部分。

  摘要：

  通过优化通过随机筛选发现的先导化合物1，已鉴定出有效的和选择性的白色念珠菌N-肉豆蔻酰转移酶（CaNmt）抑制剂。抑制剂的设计基于具有化合物（S）-3的CaNmt配合物的晶体结构，并且已经阐明了结构-活性关系（SAR）。对C-4侧链1的修饰导致发现了一种有效的选择性CaNmt抑制剂11（RO-09-4609），该抑制剂在体外对白色念珠菌具有抗真菌活性。

  DOI：

  10.1016/s0960-894x(01)00319-5

文献信息

• HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS
  申请人：Alvaro Giuseppe

  公开号：US20130267510A1

  公开（公告）日：2013-10-10

  The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

  该发明提供了化合物的公式(I)：所述化合物是Kv3通道的抑制剂，可用于预防或治疗相关疾病。
• Protein-tyrosine phosphatase inhibitors and uses thereof
  申请人：——

  公开号：US20040214870A1

  公开（公告）日：2004-10-28

  The present invention is directed to compounds of formula (I), 1 or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.

  本发明涉及式(I)的化合物，或其药用适宜盐或前药，用于选择性抑制蛋白酪氨酸磷酸酶-1B（PTP1B），并且用于治疗由过度表达或改变的蛋白酪氨酸磷酸酶1B引起的疾病。
• [EN] HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS<br/>[FR] DÉRIVÉS D'HYDANTOÏNE UTILES EN TANT QU'INHIBITEURS DE KV3
  申请人：AUTIFONY THERAPEUTICS LTD

  公开号：WO2012076877A1

  公开（公告）日：2012-06-14

  The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

  该发明提供了化合物的公式(I)：所述化合物是Kv3通道的抑制剂，可用于预防或治疗相关疾病。
• Novel flavonoids and their use in cosmetic and dermatological preparations
  申请人：——

  公开号：US20020025301A1

  公开（公告）日：2002-02-28

  Flavonoids of the formula 1 in which R is one of the radicals of the formula Ia or Ib 2 where R 1 is hydrogen or C 1 - to C 4 -alkyl, hydroxyl, C 1 - to C 4 -alkoxy, phenyloxy or benzyloxy, R 2 is hydrogen or C 1 - to C 4 -alkyl, R 3 is hydrogen, C 1 - to C 4 -alkyl, C 1 - to C 4 -alkoxy or cyano, R 4 is hydrogen, C 1 - to C 4 -alkyl or phenyl, n is 0 or 1 and Het is a pyridyl, furyl or methylpyrrolyl radical, with the proviso that when the radical R=Ia and n=0, at most 2 of the radicals R 1 to R 3 are hydrogen at the same time, and their use in cosmetic and dermatological preparations.

  公式中的黄酮类化合物 其中R是公式Ia或Ib的基团之一 其中 R 1 是氢或C 1 -至C 4 -烷基，羟基，C 1 -至C 4 -烷氧基，苯氧基或苄氧基， R 2 是氢或C 1 -至C 4 -烷基， R 3 是氢，C 1 -至C 4 -烷基，C 1 -至C 4 -烷氧基或氰基， R 4 是氢，C 1 -至C 4 -烷基或苯基， n为0或1，且 Het是吡啶基，呋喃基或甲基吡咯基基团，但当基团R=Ia且n=0时，最多有2个基团R 1 到R 3 同时为氢， 以及它们在化妆品和皮肤科制剂中的用途。
• Na+-Glucose Cotransporter Inhibitors as Antidiabetic Agents. II. Synthesis and Structure-Activity Relationships of 4'-Dehydroxyphlorizin Derivatives.
  作者：Mitsuya HONGU、Takashi TANAKA、Nobuyuki FUNAMI、Kunio SAITO、Kenji ARAKAWA、Mamoru MATSUMOTO、Kenji TSUJIHARA

  DOI：10.1248/cpb.46.22

  日期：——

  A novel series of 4'-dehydroxyphlorizin derivatives was synthesized and the effects of these compounds on urinary glucose excretion were evaluated in rats. There was a strict structural requirement for activity. Introduction of a small substituent or a flat ring at the 3- and/or the 4-position on the A ring was permissible, but any change at the bridge part between the A and B rings or in the sugar moiety resulted in complete loss of activity. The 6'-OH group on the B ring was also necessary, and even small structural modifications of the 6'-OH group reduced the activity considerably. Among the compounds synthesizez, the 5-benzofuryl derivative 25 was the most potent and was selected as a new lead for further structure-activity relationship investigations.

  合成了一系列4'-去羟基荭草苷衍生物，并评估了这些化合物对大鼠尿糖排泄的影响。活性对结构有严格的要求。在A环的3位和/或4位引入小取代基或平面环是允许的，但A环与B环之间的桥接部分或糖部分的任何改变会导致活性的完全丧失。B环上的6'-OH基团也是必要的，即使是6'-OH基团的小结构修改也会显著降低活性。在合成的化合物中，5-苯并呋喃衍生物25是最有效的，并被选为进一步结构-活性关系研究的新先导。